Pharmaceuticals segment: Operating income JPY 5.7 billion
• YoY decrease of JPY 4.3 billion
Increased sales of newly launched drugs such as Sycrest and Bilanoa
Increased sales volume of generics
Impacted by NHI price revisions, one-time license fee payments and increase in promotion expenses
• Increased by JPY 0.7 billion compared to revised plan released in February 2017
Company-wide cost control
Receipt of one-time contract payments
Licensed Safinamide, drug for Parkinson's Disease, to Eisai Co., Ltd.
• YoY decrease of JPY 4.3 billion
Increased sales of newly launched drugs such as Sycrest and Bilanoa
Increased sales volume of generics
Impacted by NHI price revisions, one-time license fee payments and increase in promotion expenses
• Increased by JPY 0.7 billion compared to revised plan released in February 2017
Company-wide cost control
Receipt of one-time contract payments
Licensed Safinamide, drug for Parkinson's Disease, to Eisai Co., Ltd.